Arcutis BiotherapeuticsNASDAQ: ARQT

We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56 For participants who achieved disease clearance and switched to proactive twice weekly application of roflumilast cream, the median duration of disease control was 281 days Once-daily, roflumilast cream 0.15% was well tolerated, with no new safety signals observed for up to 56 weeks of treatment CHICAGO and WESTLAKE VILLAGE, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15% in adults and children ages 6 years and older with AD presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference.

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.

The consensus price target hints at a 101.1% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET with Company Participants Latha Vairavan, Frank Watanabe, Todd Edwards, Patrick Burnett, and David Topper. Conference Call Participants include Serge Belanger, Seamus Fernandez, Vikram Purohit, Tyler Van Buren, and Uy Ear. Operator welcomes participants to the call and reminds them that it is currently in a listen-only mode.

Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.